Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Li

Showing results (91-100 of 155) with videos related to

Pageof 16
Sort By:
Allergy|May 27, 2020
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacksMarc A Riedl, Marcus Maurer, Jonathan A Bernstein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 20, 2023
Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING StudyMarcus Maurer, William R Lumry, H Henry Li, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|February 5, 2025
Artificial intelligence-based clinical decision support in the emergency department: A scoping reviewHashim Kareemi, Krishan Yadav, Courtney Price, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2025
Vamp3/syntaxin 4 mediates the basolateral membrane fusion of TfR transcytosis across the BBB and is exploited by pathogenic <i>E. coli</i>Bin Liu, Yingying Su, Hao Sun, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|December 12, 2023
Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysisWilliam Lumry, Timothy Craig, John Anderson, et al.
Pediatrics|December 13, 2016
Management of Children With Hereditary Angioedema Due to C1 Inhibitor DeficiencyMichael M Frank, Bruce Zuraw, Aleena Banerji, et al.
Advances in Therapy|May 2, 2026
Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment ComparisonJohn Anderson, Nihal Narsipur, Douglas Jones, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2025
Pharmacokinetics and Pharmacodynamics of neffy, Epinephrine Nasal Spray, in Pediatric Allergy PatientsDavid M Fleischer, H Henry Li, Neetu Talreja, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 30, 2011
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialWilliam R Lumry, H Henry Li, Robyn J Levy, et al.
Pageof 16

Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Allergy|May 27, 2020
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacksMarc A Riedl, Marcus Maurer, Jonathan A Bernstein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 20, 2023
Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING StudyMarcus Maurer, William R Lumry, H Henry Li, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|February 5, 2025
Artificial intelligence-based clinical decision support in the emergency department: A scoping reviewHashim Kareemi, Krishan Yadav, Courtney Price, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2025
Vamp3/syntaxin 4 mediates the basolateral membrane fusion of TfR transcytosis across the BBB and is exploited by pathogenic <i>E. coli</i>Bin Liu, Yingying Su, Hao Sun, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|December 12, 2023
Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysisWilliam Lumry, Timothy Craig, John Anderson, et al.
Pediatrics|December 13, 2016
Management of Children With Hereditary Angioedema Due to C1 Inhibitor DeficiencyMichael M Frank, Bruce Zuraw, Aleena Banerji, et al.
Advances in Therapy|May 2, 2026
Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment ComparisonJohn Anderson, Nihal Narsipur, Douglas Jones, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2025
Pharmacokinetics and Pharmacodynamics of neffy, Epinephrine Nasal Spray, in Pediatric Allergy PatientsDavid M Fleischer, H Henry Li, Neetu Talreja, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 30, 2011
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialWilliam R Lumry, H Henry Li, Robyn J Levy, et al.
Pageof 16